Absorption rates of phosphate buff ered insulin analogs aspart and lispro prevail over regular human insulin. However, insulin aspart has not been widely used. The aim of this open controlled clinical study is to compare the metabolic eff ects of insulin aspart and phosphate buff ered insulin when both are used in insulin pumps according to the identical algorithms. Methods: Twenty one persons aged 39.9 ± 2.89 (mean ± SE) years (y) with type 1 diabetes mellitus duration of 17.9 ± 2.21 y treated by an insulin pump for 4.3 ± 0.53 y (at least 3 months), educated in selfmonitoring, entered the study. Mean plasma glucose, rates of hypo-and hyperglycaemias from the glucometer memory and other data from the fi rst 256 ± 19.97 days period with regular human insulin (check-up 1 and 2) and consequent 364 ± 8.78 days long period with insulin aspart (check-up 3 and 4) were compared (paired t-test). Replacement of human regular insulin with insulin aspart after two check-ups was the only change in the treatment of diabetes. No special therapeutic education or training was made during the study. Results: In persons with type 1 diabetes treated by an insulin pump with insulin aspart, despite the lower daily dose of insulin aspart vs human regular insulin, the HbA1c decreased; the frequency of hypo-and hyperglycaemias and the BMI did not change. Conclusions: Insulin analog aspart appears to be more eff ective for continuous subcutaneous insulin infusion than regular human insulin.
INTRODUCTION
Absorption rates of the phosphate buff ered insulin analogs aspart (Novorapid, Novo Nordisk) and lispro (Humalog, Eli Lilly) prevail over regular human insulin 6, 8, 11, 13 . Due to their monomeric structure they are absorbed from the subcutaneous tissue immediately after application, whereas the hexameric form of regular insulin needs to be split into absorbable monomers fi rst. For this reason the absorbtion of regular human insulin takes about 10-20 min longer. Since the beginning of the insulin pump era in the year 1978 10 , various kinds of shortacting insulin have been used for continuous subcutaneous insulin infusion. Phosphate buff ered human insulin (Velosulin HM, Novo Nordisk) was recommended because of its low aggregability in tubing systems. In recent years good effects of insulin lispro applied in continuous subcutaneous insulin infusion have been described 9, 12 . There was also some positive experience with insulin aspart [2] [3] [4] [5] . However, insulin aspart has not been widely used. The distribution of Novorapid in the Czech Republic started as late as in Octobre 2002.
AIMS
The aim of this open controlled clinical study is to compare the eff ects of insulin aspart and phosphate buffered regular human insulin when both are used in insulin pumps according to identical algorithms: 1. on parameters of carbohydrate metabolism (P-glucose, HbA1c, S-fructosamine); 2. on parameters of lipoprotein metabolism (S-cholesterol, S-HDL-, S-LDL-cholesterol and S-triacylglycerols); 3. on clinical parameters (body mass index, blood pressure and heart rate); 4. on other biochemical parameters of mineral metabolism, liver and kidney function; 5. on patients' satisfaction.
MATERIAL AND METHODS

Persons with type 1 diabetes mellitus
Twenty one persons with type 1 diabetes mellitus treated by means of an insulin pump for least 3 months, educated
Biomed. Papers 148 (1) , 27-32 (2004) in selfmonitoring (SM) on glucometer Optium, Abbott/ Medisense, and attending routine medical check-ups at 1-to 2-month intervals, completed the study (Table 1) .
Study design
This trial was performed in the period from Janu- Table 1 ) continued as before, according to usual principles. 5. Data from two check-ups with insulin Novorapid, i.e. from a check-up about three month after the insulin change (the study check-up 3) and from a check-up about one year after the change (the study check-up 4), were registered in the study protocol. 6. Mean plasma glucose (MPG) and rates of hypo-and hyperglycaemias in the course of the 2-month period before the respective check-up were assessed from glucometer memory. 7. At the check-up 3 and 4 everyone was asked whether he/she would prefer to switch back to Velosulin HM or to go on with Novorapid and the number of local complications resulting from pump therapy was sumarized.
Statistical evaluation
Clinical and laboratory data from the fi rst period with regular human insulin Velosulin HM (check-up 1 and 2) and the consequent period with insulin aspart Novorapid (check-up 3 and 4) were compared. Correlations between HbA1c vs. total daily insulin dose and HbA1c vs. frequency of selfmonitoring were sought. 
RESULTS
Ten-point P-glucose profi les with Velosulin HM and with Novorapid are shown in Fig 1 (means) and in Fig. 2 (medians). Only the diff erence at 6:00 h was signifi cant ( p < 0.05).
The HbA1c decreased within 12 month after the change to Novorapid; at check-up 4, the diff erences vs. check-up 1, vs. check-u 2 and vs. check-up 3 were significant (Fig. 3) , even though the total daily insulin dose at PC Link (Abbott/Medisense) enabled transfer of the results of selfmonitoring from glu co me ter Optium to a PC. MS Excel and SPSS v. 10.1 were used to analyze the data. A paired t-test was applied whenever possible. p < 0.05 was considered to be of statistical signifi cance. 
Benefi ts of insulin aspart vs phosphate-buff ered human regular insulin in persons with type 1 diabetes treated by means of an insulin pump
check-up 4 vs. check-u 2 was lower (Fig. 5) as a result of to both smaller prandial boluses and smaler basal rates (Fig. 6) .
The BMI did not change (Fig. 4) . There was no signifi cant change in basal heart rate and blood pressure. Changes in laboratory parameters were exceptional (Table 2) .
No strong correlation either between HbA1c vs. daily insulin dose or between HbA1c vs. frequency of selfmonitoring could be found. (Table 2) .
Concerning the patients'satisfaction, at the check-up 3 only one person (with renal insufi ciency) would probably prefer to switch back to Velosulin HM; namely, he felt the sensations of hypoglycaemia appeared more frequently with Novorapid. After the reduction of basal rate and prandial boluses he agreed to go on with Novorapid, as well as at the check-up 4. Fourteen patients were (since the change) undoubtedly enthusiastic with Novorapid because of better fl exibility in administration of prandial boluses and generally better felt condition. Six patients would not object to go on with either Novorapid or Velosulin HM as they could not see any particular advantage in the treatment with Novorapid.
In the course of 7 800 patient-days with Novorapid, there was one local infection at the site of catheter Silhouette insertion demanding surgical intervention, and some minor problems (one or two per patient per year) with tubing system Silhouette.
DISCUSSION
The results of two check-ups in the course of the fi rst period (with Velosulin HM) may be considered as "a control group", and, as well, a stable baseline. No signifi cant diff erence between the check-up 1 and 2 were found.
Replacement of phosphate buff ered regular insulin (Velosulin HM) with insulin aspart (Novorapid) after check-up 2 was the only change in the treatment. The patients had no special training or therapeutic education and they were not aware that they are in a study. For this reason, there was (if any) only a little infl uence of the factor "improvement due to being observed" as it has been seen in some clinical studies. Hence, the signifi cant improvement of HbA1c at check-up 4 by 0.48 % vs. checkup 1 and by 0.36 % vs. check-up 2 may be considered as a benefi t of insulin aspart.
The long-term results (check-up 4) are more encouraging than the results from the fi rst 80-day period (checkup 3) where no improvement of HbA1c could be seen. Nevertheless, our results from check-up 3 correspond to the results of the multicenter randomized parallel-group study of Bode et al. (1) comparing the diff erences between insulin aspart, buff ered regular insulin and insulin lispro: 146 adult patients were randomized and no diff erences in HbA1c concentrations could be found within a 16 weeks period of insulin pump treatment.
There was only a small diff erence between the P-glucose profi les with Velosulin HM and with Novorapid. In intensive conventional insulin treatment the eff ects of Novorapid on postprandial P-glucose concentrations are emphasized 7, 14 . In continuous subcutaneous insulin treatment with intensive selfmonitoring, however, the correct basal rate and prandial boluses may better prevent the development of postprandial hyperglycaemia either with Velosulin HM or with Novorapid. It must be also taken into consideration that the timing of P-glucose measurements in ten-point selfmonitoring profi les was not absolutely precise. The patient is often known to get the best results before a check-up. Nevertheless, even though there is little statistical signifi cance between P-glucose profi les (probably due to the methodical factors mentioned), the decisive parameters to assess the eff ectiveness of insulin treatment are HbA1c, daily insulin dose and BMI.
CONCLUSIONS
In persons with the type 1 diabetes mellitus treated by an insulin pump, the benefi ts of insulin aspart (Novorapid) on metabolism of carbohydrates was demonstrated: despite the lower daily dose of insulin aspart (Novorapid) vs phosphate buff ered human regular insulin (Velosulin HM), the HbA1c decreased. The frequency of hypo-and hyperglycaemia, the BMI, blood pressure and heart rate did not change. No signifi cant infl uence of insulin aspart on selected parameters of liver or kidney functions and no other side eff ects were found. Patients' satisfaction with Novorapid was good. Hence, insulin aspart (Novorapid) appears to be more eff ective for continuous insulin infusion than phosphate buff ered regular human insulin (Velosulin HM) and may be recommended.
